Promising Early Results from the First Clinical Trial of a
Combination Regimen of 2 Oral Antiviral Agents for Chronic Hepatitis C
Combination therapy consisting of pegylated interferon (Pegasys or
PegIntron) plus ribavirin is the current standard of care for chronic
hepatitis C virus (HCV) infection, but there is an urgent need for anti-HCV
therapies that are more potent, less toxic, and more convenient. To this
end, researchers are studying several oral agents that directly target
various steps of the HCV lifecycle, an approach referred to as "STAT-C."
In a late-breaker session at the 44th Annual Meeting of the European
Association for the Study of the Liver (EASL 2009) last week in Copenhagen,
Denmark, researchers reported early promising results from a study of an
all-oral, direct-acting combination antiviral regimen consisting of the
experimental nucleoside analog polymerase inhibitor R7128 and the
experimental HCV protease inhibitor R7227 (also known as ITMN-191).
The study, called INFORM-1, is the first to test 2 direct-acting oral
antiviral agents, without interferon or ribavirin, in hepatitis C patients.
Combining 2 potent agents targeting 2 distinct viral enzymes may offer
advantages over single-agent therapy by enhancing potency, reducing the
emergence of drug resistance, and possibly eliminating the need for
pegylated interferon and/or ribavirin, the researchers noted as background.
This randomized, double-blind, ascending-dose Phase I trial included 57
treatment-naive adults with genotype 1 chronic hepatitis C. Participants
received R7128 plus R7227 oral combination therapy for up to 14 days.
Groups A and B received low dose monotherapy with either 500 mg R7128
every 12 hours (group A, n=8) or 100 mg low-dose R7227 every 8 hours (group
B, n=9) on days 1-3. Both groups then received a combination of R7128 plus
R7227 on days 4-7.
Groups C through F (8 active/2 placebo) received R7128 every 12 hours
plus R7227 every 8 hours for 14 days at the following doses: 500 mg/100 mg,
1000 mg/100 mg, 500 mg/200 mg, and 1000 mg/200 mg.
The investigators evaluated safety, viral kinetics, resistance, and
pharmacokinetics of R7128 plus R7227 in all groups. None of the participants
received pegylated interferon or ribavirin.
Groups A through C (n = 27) completed the study with no treatment-related
serious adverse events (SAEs), dose modifications, or discontinuations.
Pharmacokinetic analysis confirmed no drug-drug interactions between R7128
The mean decrease in HCV RNA from baseline was similar in Groups A and B at
Overall, the mean change in HCV RNA from baseline ranged from -4.8 to -5.2
log10 IU/mL using the highest doses tested.
The combination of R7128 plus R7227 provided greater than additive antiviral
No viral rebound (sustained viral load increase > 0.5 log10) was observed.
Approximately 63% of patients experienced a decrease in HCV RNA to below the
quantification limit of the diagnostic assay.
25% of patients in the highest dose groups had undetectable HCV in their
blood after 14 days.
These findings led the investigators to conclude, "The orally administered
combination of low dose R7128 and R7227 provided significant antiviral
potency, suppressed viral rebound, and appears safe and well-tolerated for
"These results confirm for the first time that a protease and nucleoside
polymerase inhibitor can be combined in vivo, and remain a promising
combination for future treatment," they added
A press release from Roche announced that Roche, InterMune, and Pharmasset
-- the 3 companies collaborating on development of this combination regimen
-- are now exploring twice-daily dosing of R7227 and higher total daily
doses (600 mg twice-daily and 900 mg twice-daily) than those used in the
In addition to clinical trials of combination direct-acting antiviral
regimens such as those studied in INFORM-1, R7227 and R7128 are each
"proceeding rapidly in development" in combination with Roche's pegylated
interferon alfa-2a (Pegasys) plus ribavirin (Copegus), the announcement
stated. A Phase 2b study with R7128 is now underway, while a Phase 2b study
with R7227 is slated to begin this summer.
Auckland Clinical Studies, Auckland, New Zealand; Alfred Hospital,
Melbourne, Victoria, Australia; Christchurch Clinical Studies, Christchurch,
New Zealand; Austin Hospital, Heidelberg, Victoria, Australia; Royal
Adelaide Hospital, Adelaide, Australia; Roche Palo Alto LLC, Palo Alto, CA;
Pharmasset, Inc., Princeton, NJ; Intermune, Inc., Brisbane, CA.
EJ Gane, SK Roberts, C Stedman, and others. First-In-Man Demonstration of
Potent Antiviral Activity with a Nucleoside Polymerase (R7128) and Protease
(R7227/ITMN-191) Inhibitor Combination in HCV: Safety, Pharmacokinetics, and
Virologic Results from INFORM-1. 44th Annual Meeting of the European
Association for the Study of the Liver (EASL 2009). Copenhagen, Denmark.
April 22-26, 2009. Late-breaker Abstract 1046.
Roche Laboratories. Ground-breaking Combination of All-oral Agents
Demonstrates Potential as Hepatitis C Treatment Regimen. Press Release.
April 25, 2009.